JANX vs. RYTM, DYN, ACAD, INDV, PTCT, MLTX, BHC, MRUS, MRVI, and VERA
Should you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Rhythm Pharmaceuticals (RYTM), Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD), Indivior (INDV), PTC Therapeutics (PTCT), MoonLake Immunotherapeutics (MLTX), Bausch Health Companies (BHC), Merus (MRUS), Maravai LifeSciences (MRVI), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical preparations" industry.
Janux Therapeutics (NASDAQ:JANX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.
Janux Therapeutics has a beta of 3.87, suggesting that its stock price is 287% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500.
Rhythm Pharmaceuticals received 253 more outperform votes than Janux Therapeutics when rated by MarketBeat users. Likewise, 65.71% of users gave Rhythm Pharmaceuticals an outperform vote while only 62.16% of users gave Janux Therapeutics an outperform vote.
Janux Therapeutics presently has a consensus price target of $69.50, indicating a potential upside of 44.82%. Rhythm Pharmaceuticals has a consensus price target of $54.33, indicating a potential upside of 39.46%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Janux Therapeutics is more favorable than Rhythm Pharmaceuticals.
Janux Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Janux Therapeutics is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Rhythm Pharmaceuticals has a net margin of -297.91% compared to Janux Therapeutics' net margin of -762.92%. Janux Therapeutics' return on equity of -13.49% beat Rhythm Pharmaceuticals' return on equity.
In the previous week, Janux Therapeutics had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 9 mentions for Janux Therapeutics and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.60 beat Janux Therapeutics' score of 0.37 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.
75.4% of Janux Therapeutics shares are owned by institutional investors. 35.4% of Janux Therapeutics shares are owned by insiders. Comparatively, 5.6% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Janux Therapeutics beats Rhythm Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Janux Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Janux Therapeutics Competitors List
Related Companies and Tools
